News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors MARCH 22, 2021 PDF Version Checkpoint therapy alone is unlikely to lead to durable tumor control or a cure in patients with solid tumors that harbor DNA mutations that make them invisible to T cells This study supports ImmunityBio’s hypothesis of combining NK cells with T cell activation in Phase 2/3 trials in metastatic pancreatic and lung cancers Preclinical study shows when tumor cells escape T cell detection or killing, tumor cell PD-L1 expression is increased thereby sensitizing these resistant cells to killing by ImmunityBio’s PD-L1 t-haNK cells https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-nih-led-research-affirming-pd-l1-t-hank?field_nir_news_date_value[min]=

WOULD YOU TAKE COVID VACCINE IN PILL FORM? BIOVAC EXPLORING THIS POSSIBILITY On Thursday, Biovac announced a local manufacturing partnership with US-based immunotherapy firm - ImmunityBio. https://www.google.com/amp/s/ewn.co.za/2021/03/19/would-you-take-covid-vaccine-in-pill-form-biovac-exploring-possibility/amp

ImmunityBio's COVID-19 Vaccine Will Be Manufactured In South Africa: Bloomberg https://newsfilter.io/a/fad16a7a341d310af9100dce4baa8cec

NZIMANDE EXCITED ABOUT VACCINE PARTNERSHIP BETWEEN BIOVAC & IMMUNITYBIO The collaboration aims to develop capability in South Africa for the full value-chain manufacturing of vaccines. https://ewn.co.za/2021/03/18/nzimande-announces-manufacturing-partnership-between-sa-s-biovac-and-us-firm-immunitybio

Ich sehe positive Ergebnisse bei Tests auf Verträglichkeit immer als absolutes Minimum. Da sind keine großen Kurssprünge zu erwarten.

https://www.webull.com/news/39696425 Gute News

Ist auch ein paar Tage älter, aber deswegen nicht weniger interessant, deswegen stelle ich die Interviews umd Diskussionen noch mal ein: Soon Shiong on BioTech and the future of newspapers: https://youtu.be/gERAPHT3pN4 Wits in conversation with Dr. Patrick Soon Shiong: https://youtu.be/C7myUglWNHE

👀

About ImmunityBio ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.” ImmunityBio has an unparalleled immunotherapy pipeline with more than 40 clinical trials (company sponsored or investigator initiated)—of which 25 are at Phase II and III stage of development—across 19 indications in solid and liquid cancers and infectious diseases. Currently 17 first-in human immunotherapy agents are in clinical testing and, to date, over 1,800 patients have been studied with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf natural killer cell products. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). The company’s platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells. ImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations and development teams. For more information, please visit: www.immunitybio.com